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Abstract 
Xanthone derivatives have been described as compounds with privileged scaffolds that exhibited diverse 
interesting biological activities, such as antitumor activity, directing the interest to pursue the 
development of these derivatives into drug candidates. Nevertheless, to achieve this purpose it is crucial 
to study their pharmacokinetics and toxicity (PK/tox) as decision endpoints to continue or interrupt the 
development investment. This review aims to expose the most relevant analytical methods used in 
physicochemical and PK/tox studies in order to detect, quantify and identify different bioactive 
xanthones. Also the methodologies used in the mentioned studies, and the main obtained results, are 
referred to understand the drugability of xanthones derivatives through in vitro and in vivo systems 
towards ADME/tox properties, such as physicochemical and metabolic stability and biovailability. The 
last section of this review focus on a case-study of the development of the drug candidate DMXAA, 
which has reached clinical trials, to understand the paths and the importance of PK/tox studies. In the end, 
the data assembled in this review intends to facilitate the design of potential drug candidates with a 
xanthonic scaffold. 
 
Xanthone; analytical method; drug-like; pharmacokinetics; toxicity; drug development; preclinical; 
metabolism; chromatography. 
 
1. Introduction 
The xanthone nucleus or 9H-xanthen-9-one (dibenzo-γ-pirone 1, Fig. 1) comprises an important 
class of oxygenated heterocycles and is considered a privileged structure 1. It includes relevant secondary 
metabolites which are present in commercialized extracts with human health promotion properties 2. 
Considering synthetic derivatives, one compound emerged as drug candidate, 5,6-dimethylxanthenone-4-
acetic acid (DMXAA, Vadimezan, ASA404, 2, Fig. 1) and reached phase III clinical trials towards 
antitumor activity 3. Due to a great number of studies in isolation, synthesis and 
biological/pharmacological properties of xanthone derivatives, several reviews 1,4-16 have gathered 
important information to guide the design of these compounds as potential drug candidates. Nevertheless, 
little focus was given to drug pharmacokinetics (PK), toxicity studies, and structure-properties 
relationships of xanthone derivatives.  
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Fig. 1: Xanthone (1) and DMXAA (2). 
Nowadays it is recognized that in addition to pharmacological properties, PK and toxicological 
properties are crucial determinants of the ultimate clinical success of a drug. This recognition has led to 
the early introduction of absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) 
screening during the drug discovery process, in an effort to filter drugs with problematic ADME/Tox 
profiles. Prior to the early 1980s, for example, PK studies in the pharmaceutical industry were largely 
detailed and were primarily focused on clinical development efforts in support of product registration, 
with little attention being devoted to the PK characteristics of new chemical entities and to mechanistic 
insight into the fate of candidate drugs in biological systems. The fact that the primary reason for failure 
of drug candidates in clinical development during the 1960s and 1970s was judged to be due to 
inappropriate human PK led to the progressive integration of PK studies as a key component of the 
overall drug discovery process 17. This shift was relatively easily accomplished using existing 
methodologies and, currently, development attrition due to PK properties is no longer the bottle-neck in 
drug discovery and development 18. 
The optimization of a large number of variables is required early in the design and evaluation of the 
chemical entities to increase the probability of finding clinical candidates not only of complex parameters 
related to toxicity and bioavailability but also the most favorable physicochemical properties (i.e., 
molecular weight, solubility, polar surface area, lipophilicity, among others). The importance of these 
properties in drug design has always been recognized in an implicit manner in structure-activity 
relationship studies; nevertheless, it is established that analyzing the data of these properties makes more 
probable the success in drug discovery 19.  
The physicochemical properties of some investigated xanthone derivatives suggest that they might 
exhibit high bioavailability, an important factor contributing to their efficacy and success as drug 
candidates. However, studies involving drug-like properties of xanthone derivatives are sparse. This 
review provides an opportunity to organize the emerging data concerning the methods used to investigate 
PK and physicochemical properties of bioactive xanthone derivatives. Firstly, the most relevant analytical 
methods and conditions are described for xanthones from different sources (natural, metabolic, or 
synthetic) and classes (prenylated, glycosylated, carboxylated). Following, methodologies and results 
involved in drug-like properties characterization are revised. At the end of this review, a case-study of the 
drug DMXAA (2) highlights the rational of PK studies in the drug discovery and development pipeline. 
The methodologies and data gathered in this review may pave the way for the design of potential drug 
candidates with a xanthonic scaffold. 
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2. Chromatographic methods applied to xanthones in preclinical and clinical studies 
Chromatographic methods have been used to study drugs and their PK behavior, namely gas 
chromatography – mass spectrometry (GC-MS) and liquid chromatography (LC) with ultraviolet (UV), 
fluorescence, radioactivity and MS detection systems, being the late one probably the most applied 
nowadays, both in in vitro and in vivo studies 20,21. In the case of LC-MS, the LC (usually HPLC – High 
Performance Liquid Chromatography - or UPLC – Ultra Performance Liquid Chromatography) allows 
the separation of the different components present in the sample and the MS enables the identification of 
the compounds previously separated in the chromatographic method 22.  
The establishment of quantitative structure-property relationships for xanthone derivatives is a major 
focus of interest for PK studies. The use of reversed-phase HPLC coupled with a UV detector has been 
developed in order to describe the behavior of xanthone derivatives according to a model in which both 
the molecular structure parameters and mobile phase properties are taken into consideration. Appling this 
method, the chromatographic behavior of xanthone derivatives are dependent of the solvent properties 
(polarity/polarizability parameter, hydrogen-bond basicity) and solute properties (most positive local 
charge, the sum of positive charges on hydrogen atoms contributing in hydrogen interaction and 
lipophilicity index (Log P)) 23. Another chromatographic technique that can be applied in the evaluation 
of lipophilicity of xanthone derivatives is micellar electrokinetic chromatography, since the separation 
selectivity of xanthones can be modulated by changing the micellar phase or aqueous phase between 
which the analytes are partitioned, being this behavior closely associated with the hydrophobicity of the 
compounds 24. Techniques such as capillary zone electrophoresis (CZE), measuring the mobility of a 
given solute as a function of pH, is a reliable method to determine dissociation constants (pKa) for 
pharmacologically active xanthones 25. 
 
2.1. Natural xanthones 
Due to the wide distribution of xanthonic compounds in many natural products used in folk 
medicine, in the last decade the study of methods to purify, isolate, identify and analyze these derivatives 
has become an important goal in Medicinal Chemistry 5,6,24. Several natural xanthones are currently 
undergoing preclinical studies. 
One example of these compounds is mangiferin (3, Fig. 2) an hydroxylated and glycosylated 
xanthone that was originally isolated from Mangifera indica L. and has already been reported to have 
several pharmacological activities, such as antitumor, antiviral, antidiabetic, among others 1. For all these 
reasons, many research groups have found great interest in studying the PK behavior of this compound, 
through chromatographic methodologies (Table 1).  
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Fig. 2: Chemical structure of mangiferin (3). 
 
Table 1: Chromatographic methods applied to PK studies of mangiferin (3). 
PK study Sample 
Chromatographic 
method 
Chromatographic 
conditions 
Ref. 
Quantification after oral 
administration of 
mangiferin-hydroxypropyl-
β-cyclodextrin inclusion 
Rat plasma 
HPLC-DAD 
(258 nm) 
MP – methanol:0.6% 
glacial acetic acid solution 
(27:73) 
SP – C18 
FR – 1 mL/min 
26 
Blood-ocular barrier 
permeability after oral 
administration of 
Mangiferin-hydroxypropyl-
β-cyclodextrin inclusion 
Rat eye fluid 
HPLC-DAD 
(258 nm) 
MP – methanol:0.6% 
glacial acetic acid solution 
(27:73) 
SP – C18 
FR – 1 mL/min 
26 
Simultaneous determination 
of 3, neomangiferin and 
other active components 
after oral administration of 
Zi-Shen Pill extract 
Rat plasma LC-ESI-MS/MS 
MP  - acetonitrile:0.1% 
formic acid solution in 
gradient program 
SP – C18 
FR – 0.25 mL/min 
27 
Chemical profile of 3 and 
other active components 
after oral administration of 
Shengxian Decoction 
Rat plasma UPLC-Q-TOF-MS 
MP – 0.01% formic acid 
solution with 0.1 mM 
ammonium acetate: 
acetonitrile (85:15) 
SP – C18 
FR – 0.25 mL/min 
28 
Glucuronidation of 3 Rat liver 
HPLC-DAD 
(320 nm) and 
LC-MS2 
MP – acetonitrile:0.1% 
formic acid solution in 
gradient program 
SP – C18 
FR – 1 mL/min 
29 
Metabolism of 3 after oral 
administration 
Rat urine, plasma, 
feces, liver, 
kidneys, heart, 
spleen, lung and 
intestinal tract 
contents 
LC-ESI-IT-MSn 
MP - acetonitrile:0.5% 
formic acid solution in 
gradient program 
SP – C18 
FR – 0.8 mL/min 
30 
Identification of 3 and other 
bioactive components of 
Zhimu-Huangqi herb-pair 
extract and their metabolites 
after oral administration 
Rat plasma and 
urine 
LC-ESI-MSn 
MP - acetonitrile:0.2% 
formic acid solution in 
gradient program 
SP – C18 
FR – 1.0 mL/min 
31 
MP – mobile phase; SP – stationary phase; FR – flow rate; DAD – diode array detector; TOF – time of 
flight; Q – quadrupole; LC – liquid chromatography; ESI – electrospray ionization; IT – ion trap; MS – 
mass spectrometry. 
 
Other important representatives of natural xanthones with biological interest are α-mangostin (4, 
Fig. 3) and γ-mangostin (5, Fig. 3), prenylated xanthones present in high concentrations in the pericarp of 
Garcinia mangostana L. These compounds have shown antioxidant, anti-inflammatory and antitumor 
activities, among others 1,14,32-34. Due to the increasing interest and knowledge of the mechanisms behind 
the biological activities of mangosteens, several studies have been carried out over the last years to 
understand the PK proprieties of these compounds, using chromatographic methods (Table 2). 
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Fig. 3: Chemical structures of α-mangostin (4) and γ-mangostin (5). 
 
Table 2: Chromatographic methods applied to PK studies of α-mangostin (4) and γ-mangostin (5). 
PK study 
Sample/ 
Matrix 
Chromatographic 
method 
Chromatographic 
conditions 
Ref. 
Quantification of 4 and 
5 after oral and 
intravenous 
administration of 
Mangosteen extract 
Mouse plasma 
HPLC-MS/MS  
 
MP – acetonitrile 
containing 0.1% formic 
acid:0.1% formic acid 
solution (70:30) 
SP – C18 
FR – 0.35 mL/min 
35 
Tissue distribution of 
xanthones and their 
phase II metabolites 
Mouse liver, 
tumor, feces and 
serum 
HPLC-DAD and 
HPLC-MS 
MP – acetonitrile  
containing 2% acetic 
acid solution: n-butanol 
in a gradient program 
SP – C18 
FR – 0.5 mL/min 
32,36 
In vitro study of the 
intestinal uptake, 
retention, transport and 
metabolism of 4 
Caco-2 human 
intestinal cells 
HPLC-DAD 
(254 nm) 
MP – acetonitrile: 2% 
acetic acid solution in a 
gradient program 
SP – C18 
FR – 0.8 mL/min 
37 
Study of absoption, 
tissue distributon and 
tissue metabolism of 4 
after oral and 
intravenous 
administration 
Mouse plasma, 
liver stomach, 
small and large 
intestines, lung, 
heart, 
kidney, fat, 
mesentery, 
muscle and 
brain 
HPLC-MS/MS 
MP – acetonitrile 
containing 0.1% formic 
acid:0.1% formic acid 
solution (70:30) 
SP – C18 
FR – 0.35 mL/min 
38 
PKs of 4 after oral and 
intravenous 
administration  
Rat plasma LC-MS/MS 
MP – acetonitrile 
containing 0.05% formic 
acid:0.05% formic acid 
solution (80:20) 
SP – C18 
FR – 0.5 mL/min 
39 
MP – mobile phase; SP – stationary phase; FR – flow rate; DAD – diode array detector; LC – liquid 
chromatography; MS – mass spectrometry. 
 
Several other xanthones, isolated from natural sources have been investigated by chromatographic 
methods to obtain information about their PK proprieties (Table 3): the cytotoxic gambogic acid (6, Fig. 
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4), a polyprenylated xanthone isolated from the resin of several Garcinia species 40; the vasorelaxing and 
antihypertensive 1-hydroxyl-2,3,5-trimethoxy-xanthone (7, Fig. 4) isolated from the a Tibetan medicinal 
herb Halenia elliptica D. Don 41, the xanthone glycoside sibiricaxanthone F (8, Fig. 4), isolated from 
Polygala sibirica L., which has shown in vitro effect on peroxisome proliferator-activated receptors 
(PPARs) and in accelerating the differentiation of 3T3-L1 preadipocytes cells 42; the promising antitumor 
compound cudratricusxanthone B (9, Fig. 4), an isoprenylated xanthone isolated from Cudrania 
tricuspidata (Carr.) Bur. 43. 
 
 
 
Fig. 4: Chemical structures of gambogic acid (6), 1-hydroxy-2,3,5-trimethoxy-xanthone (7), 
sibiricaxanthone F (8), and cudratricusxanthone B (9).  
 
Table 3: Chromatographic methods applied to PK studies of other natural xanthones (6-9).  
PK study  Sample 
Chromatographic 
method 
Chromatographic conditions Ref. 
Quantification of 6 
after intravenous 
administration 
Dog plasma 
HPLC-UV detector 
(360 nm) 
MP – methanol:0.05% 
phosphoric acid solution (94:6) 
SP – C18 
FR – 1.0 mL/min 
44 
Identification of 
metabolites of 6 after 
intravenous 
Rat bile LC-TOF-IT-MS 
MP – acetonitrile:0.05% acetic 
acid solution in gradient 
program 
45 
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administration SP – C18 
FR – 0.2 mL/min 
Structure elucidation 
of metabolites of 6 
after intravenous 
administration 
Rat bile 
HPLC-UV (280 
nm), LC-ESI-IT-
MSn and LC-NMR 
MP – methanol:water (85:15) 
SP – C18 
FR – 1.0 mL/min 
46 
In vitro identification 
of cytochrome P450 
isoforms responsible 
for the metabolism of 
7 
Human liver 
microsomes 
LC-IT-TOF-MSn 
MP – acetonitrile:0.5%acetic 
acid solution in gradient 
program 
SP – C18 
FR – 0.8 mL/min 
47 
In vitro metabolite 
characterization of 7 
and other bioactive 
xanthones 
Rat liver 
microsomes 
LC-IT-TOF-MSn 
MP – acetonitrile:0.5%acetic 
acid solution in gradient 
program 
SP – C18 
FR – 0.8 mL/min 
41 
Quantification of 8 
after oral and 
intravenous 
administration 
Rat plasma LC-ESI-MS/MS 
MP – acetonitrile containing 
0.01% formic acid:0.01% 
formic acid solution in gradient 
program 
SP – C18 
FR – 0.4 mL/min 
48 
In vitro metabolite 
characterization of 8 
Human and 
rat liver 
microsomes 
HPLC-EMS-IDA-
EPI 
MP – acetonitrile containing 
0.1% formic acid:0.1% formic 
acid solution in gradient 
program 
SP – C18 
FR – 0.3 mL/min 
42 
Quantification of 9 
after intravenous 
administration 
Rat plasma HPLC-ESI-MS/MS 
MP – 0.5% formic acid in 
methanol 
SP – C18 
FR – 0.3 mL/min 
43 
MP – mobile phase; SP – stationary phase; FR – flow rate; TOF – time of flight; LC – liquid 
chromatography; NMR – nuclear magnetic resonance; ESI – electrospray ionization; IT – ion trap; EMS - 
enhanced mass spectrum; IDA - information dependent acquisition; EPI - enhanced product ion ; MS – 
mass spectrometry. 
  
 
2.2. Synthetic xanthone derivatives 
 
Due to the pharmacological interest in xanthone derivatives, several research groups work in the 
synthesis of xanthonic compounds in an attempt to find new drug candidates with better 
pharmacodinamic and PK properties. Table 4 shows different classes of synthetic derivatives, namely 
thioxanthones, in preclinical studies, and the applications of chromatographic methods in their PKs 
proprieties studies. It also displays the PK study of the 9H-xanthen-9-one (1) - in an in vivo model 49. 
The development of an HPLC methodology to determine the amount of a thioxanthone drug 
candidate (10, Fig. 5) and its metabolites in plasma was applied to determine effective and toxic doses, as 
well as to predict and quantify the metabolic profile of the drug candidate in in vivo tests 50.  
The intestinal absorption of a xanthonolignoid (11, Fig. 5), a protein kinase C inhibitor, was studied 
in our group, using Caco-2 cell lines as a model to predict the absorption of the drug candidate, using a 
HPLC to quantify the cell permeability 51.  
A pyranoxanthone derivative (12, Fig. 5) with potential antitumor activity intestinal absorption was 
also studied applying the same chromatographic technique. Another HPLC methodology was developed 
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to evaluate the improvement of absorption and therefore enhancement of biological activity at lower 
doses of compound 12 by inclusion into drug delivery systems, namely PLGA nanoparticles 51,52.  
 
 
 
 
Fig. 5: Chemical structures of a thioxanthone derivative 10, a xanthonolignoid 11 and a pyranoxanthone 
12. 
 
 
Table 4: Chromatographic methods applied to PK studies of synthetic xanthones (1, 10-12). 
 
PK study Sample 
Chromatographic 
method 
Chromatographic conditions Ref. 
Determination of 1 
after oral and 
intravenous 
administration 
Rat plasma 
HPLC-DAD 
(254 nm) 
MP – acetonitrile containing 
0.1% trifluoroacetic acid:0.1% 
trifluoroacetic acid solution in a 
gradient program 
SP – C18 
FR –  mL/min 
49 
Quantification of 
10 and its 
metabolites  
Mouse plasma 
HPLC-DAD 
(266 nm) 
MP - methanol:10 mM 
phosphate buffer pH 3.5 (45:55)                                                        
SP - C18                                                                                         
FR - 0.8 mL/min (10'), 
1.4mL/min (15')       
50
Prediction of 
intestinal 
absorption of 11 
Caco-2 cell 
monolayers as an 
intestinal model 
HPLC-DAD 
(237 nm) 
MP - methanol:water (85:15)                                           
SP - C18                                                                            
FR - 1 mL/min 51 
Prediction of 
intestinal 
absorption of 12 
HPLC-DAD  
(254 nm) 
MP - methanol:water (80:20)                                           
SP - C18                                                                            
FR - 1 mL/min 
Study of the 
intracellular 
delivery of 12 
entrapped in PLGA  
nanoparticles 
MCF-7 culture 
cell lines exposed 
to the xanthone 
derivative 
included in 
nanocapsule 
formulation 
HPLC-DAD  
(254 nm) 
MP - methanol:water (85:15)                                           
SP - C18                                                                            
FR - 1 mL/min 
52,53
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MP – mobile phase; SP – stationary phase; FR – flow rate; DAD – diode array detector. 
  
The introduction of a drug candidate in human trials is a highly demanding and expensive process. 
Therefore, only the drug candidates with best results in preclinical studies achieve this level in the 
pipeline of drug development 22. DMXAA (2, Fig.1) is a drug candidate that reached clinical trials and 
the chromatographic methods and conditions applied to PK studies are highlighted in Table 5. 
 
Table 5: Chromatographic methods applied to PK studies of DMXAA (2). 
 
PK study  Sample 
Chromatographic 
method 
Chromatographic conditions Ref. 
Determination of 
major metabolites of 
2 
Human liver 
microsomes 
HPLC-fluorescence 
detector (345 and 
409 nm) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76 or 19:81, according to 
the metabolite)                                           
SP - C18                                                                            
FR – 1.5 or 2.5 mL/min 
54,55 
Plasma disposition, 
metabolism and 
excretion of  2 after 
intravenous 
administration 
Mouse, rat 
and rabbit 
plasma and 
urine 
HPLC-fluorescence 
detector (for 
quantification of 
DMXAA in plasma 
and urine) 
MP – water:acetonitrile:acetic 
acid (60:40:2) 
SP - C18                                                                            
FR – 1.8 mL/min 
56-58 
HPLC-UV detector 
(254 nm) (for 
isolation of urinary 
metabolites) 
MP – 14 mM diammonium 
hydrogen phosphate 
buffer:isopropyl alcohol 
(80:20)                                           
SP - C18                                                                            
FR – 1 mL/min 
Gender differences in 
metabolism and PKs 
of 2 
Human, rat 
and mouse 
plasma and 
liver 
microsomes 
LC-MS 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 1.0 mL/min 59,60 
HPLC-fluorescence 
detector (345 and 
409 nm) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 2.0 mL/min 
Influence of other 
anticancer drugs on 
the metabolism of 2 
Human liver 
microsomes 
HPLC-fluorescence 
detector (345 and 
409 nm) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 2.5 mL/min 
61 
Identification of the 
human liver 
cytochrome P450 
isoenzyme 
responsible for the 6-
methylhydroxylation 
of 2 
Human liver 
microsomes 
LC-MS 
(Identification of the 
metabolite) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 1.0 mL/min 59 
HPLC- fluorescence 
detector (345 and 
409 nm) 
(Quantification of 
the metabolite) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 2.5 mL/min 
Quantification of 
unbound 2 in plasma 
Human 
plasma 
HPLC- fluorescence 
detector (345 and 
409 nm) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
62,63 
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FR – 2.5 mL/min 
Identification and 
reactivity of the 
major metabolite of 2 
Rat, mouse, 
rabbit and 
human 
plasma and 
human urine 
HPLC-fluorescence 
detector (345 and 
409 nm) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76 and 19:81, depending 
on the metabolite) 
SP - C18                                                                            
FR – 2.5 mL/min and 2.0 
mL/min (depending on the 
metabolite) 
54,56,59,64 
HPLC-fluorescence 
detector (345 and 
409) 
MP – water:acetonitrile:acetic 
acid (60:40:2) 
SP - C18                                                                            
FR – 1.8 mL/min 
Interspecies 
differences in the 
metabolism of 2 
Rat, mouse, 
rabbit and 
human liver 
microsomes 
LC-MS 
(Identification of the 
metabolite) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 1.0 mL/min 54,59,65 
HPLC- fluorescence 
detector (345 and 
409 nm) 
(Quantification of 
the metabolite) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 2.5 mL/min 
Interspecies 
differences in the 
plasma protein 
binding and blood 
cells distribution of 2 
Rat, mouse, 
rabbit and 
human 
plasma 
HPLC- fluorescence 
detector (345 and 
409 nm) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 2.5 mL/min 
56,66 
Strain differences in 
the metabolism of 2 
and its correlation 
with the maximum 
tolerated dose 
Five different 
mouse strains 
liver 
microsomes 
HPLC-MS-
APCI/ESP 
(Identification of the 
metabolite) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 1.0 mL/min (for HPLC-
MS-APCI) or 0.5 mL/min (for 
HPLC-MS-ESP) 
54,59,64,67 
HPLC- fluorescence 
detector (345 and 
409 nm) 
(Quantification of 
the metabolite) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 2.5 mL/min 
Impact of preclinical 
factors in the 
clearance of 2 
Human 
plasma and 
liver 
microsomes 
LC-MS 
(Identification of the 
metabolite) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 1.0 mL/min 68 
HPLC- fluorescence 
detector (345 and 
409 nm) 
(Quantification of 
the metabolite) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(24:76) 
SP - C18                                                                            
FR – 2.5 mL/min 
Quantification of 
unbound 2 in plasma 
Human 
plasma 
LC-MS/MS 
MP – acetonitrile containing 
0.1% formic acid:0.1% formic 
acid solution in gradient 
program 
SP - C18                                                                            
FR – 0.5 mL/min 
69 
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Determination of 
plasma and urine 
concentration of 2 
and its metabolites 
after intravenous 
administration  
Human 
plasma, red 
cells, urine 
and tumor 
samples 
HPLC- fluorescence 
detector (345 and 
409 nm) 
MP – acetonitrile:10 mM 
ammonium acetate buffer 
(25:75) 
SP - C18                                                                            
FR – 2.0 mL/min 
70,71 
Determination of 
[14C] ASA404 and its 
metabolites  
after intravenous 
administration 
Human 
plasma and 
feces 
HPLC - off-line 
radioactivity 
detector 
MP – gradient elution 
consisting of solvent A (5 mM 
ammonium formate with 0.1% 
formic acid, pH~3) and B 
(acetonitrile with 0.1% formic 
acid) 
SP - Waters Xbridge column                                                                           
FR – 1.0 mL/min 
72 
Determination of 2 
and its acyl 
glucuronide Caco-2 
cell monolayers for 
transport studies 
Caco-2 cell 
monolayers  
HPLC- fluorescence 
detector (345 and 
409 nm) 
MP – acetonitrile:10 mM 
ammonium acetate buffer, pH 
5.0 (24:76) 
SP - C18                                                                            
FR – 1.2 mL/min 
73  
MP – mobile phase; SP – stationary phase; FR – flow rate; LC- liquid chromatography; MS – mass 
spectrometry; APCI/ESP - Atmospheric pressure chemical ionization/electrostatic precipitator. 
 
 According to all these data, it is possible to verify that the most commonly applied 
chromatographic method is LC, especially HPLC, using a C18 stationary phase in reversed phase, using 
mixtures of water and an organic solvent, most commonly acetonitrile or methanol. The detection method 
applied depends on the nature of the analyte and the aim of the PK work, being fluorescence and diode 
array detectors widely used for quantitative analysis and identification of compounds, especially when 
standards are available. In metabolism studies and identification of xanthone derivatives and its 
metabolites, mass spectrometers detectors appear to be the most applied, due to the sensitivity, reliability, 
specificity and information that can be assessed.  
 
3. Physicochemical properties and preformulation studies of xanthone derivatives 
The discovery of new drugs needs a thorough investigation for its safety and efficacy before their 
release into the market. The old paradigm of drug discovery process has changed due to technology 
innovation. Rational drug discovery requires an early appraisal of all factors impacting on the likely 
success of a drug candidate in the subsequent preclinical, clinical and commercial phases of drug 
development. Important preformulation considerations include solubility, stability, pka, all properties that 
affect drug permeability and distribution. The next sections highlight the main structure-properties 
relationships established from the analysis of xanthone derivatives.  
 
3.1. Solubility 
Solubility is emerging as one of the major issues in drug discovery and development of new 
chemical entities 74. Compounds with low solubility not only cause problems for in vitro and in vivo 
assays, but also have a higher risk of attrition in the drug discovery pipeline 75.  
Lipinski has classified the solubility ranges (high is > 60 g/mL, moderate is 10-60 g/mL, low is < 10 
g/mL) to provide a general guideline for achieving acceptable human absorption for compounds with 
average potency and permeability. This classification is different from the Biopharmaceutics 
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Classification Systems whereas, for example, for a 1 mg/kg intravenous (I.V.) dose in rat with an ideal 
dosing volume of 1-5 mL/kg, the required concentration is 0.2 – 1 mg/mL 76. 
Different analytical tools (i.e., light scattering/turbidity, UV plate reader, LC-UV and LC–MS/LC-
CLND - chemiluminescence nitrogen) can be used for detection of the maximum amount of a compound 
that can remain in solution at a certain volume of solvent, temperature, and pressure, under equilibrium 
conditions. The pH of the buffer in solubility methods is typically 6.5 (intestine) or 7.4 (blood).  
α-Mangostin (4) showed poor aqueous solubility and low oral bioavailability, hindering its 
therapeutic application. The aqueous solubility of free α-mangostin (4) was found to be 0.2 ± 0.2 µg/mL 
77. Briefly, an excess amount from the samples was added to phosphate-buffered saline (PBS) at pH 7.4 
(Scheme 1). The mixtures were mixed and then centrifuged. The supernatant was collected, filtered and 
diluted in methanol. The samples were then analyzed using a spectrophotometer at 243.4 nmto determine 
α-mangostin (4) concentration 77. 
 
 
 
Scheme 1: Schematic representation of the solubility assay. 
 
Other study investigated the thermodynamic solubility in water at pH 7.4 HEPES (N-2-
hydroxyethylpiperazine-N-2-ethane sulfonic acid) buffer of 12-hydroxy-2,2-dimethyl-3,4-
dihydropyran[3,2b]xanthene-6(2H)-one (12) and five of its analogues bearing substituents on ring A 75. 
All compounds showed low solubility (0.1-0.6 µM) which was explained by the high planarity and 
rigidity of these compounds. Each compound was added to 2 mL of HEPES buffer until a saturated 
solution was obtained (Scheme 2). The suspension of each compound was agitated at 37 °C for 24 h. 
Each sample was filtered through a 0.1 µm filter and 1485 µL of each filtrate was added to another 
eppendorf containing 15 µL of DMSO. The UV/Vis spectrum was traced in a double-beam 
spectrophotometer and the concentration was determined according to the standard calibration curve for 
each compound. 
 
 
Scheme 2: Schematic representation of the thermodynamic solubility assay. 
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Oxo-9H-xanthene-3,6-diyl bis(3-chlorobenzoate), 9-oxo-9H-xanthene-3,6-diyl bis(4-tert-
butylbenzoate) and 9-oxo-9H-xanthene-3,6-diyl bis(4-methoxybenzoate) also showed poor water 
solubility. This limitation was successfully overcome with the formulation of these derivatives into 
cyclodextrins 78. 
The intrinsic aqueous solubility of 40 structurally diverse Garcinia natural-product-like xanthones 
based on gambogic acid (6) was determined. All the synthetic compounds displayed aqueous solubility 
that was improved over that of gambogic acid. Among all the tested compounds, the most soluble 
exhibited an intrinsic solubility of 10.37 mM, almost 1000 times more soluble than gambogic acid. Some 
structure-properties were drawn: hydrophilic amine substitution, a hydroxyl group at position 1, and 
removal of the gem-dimethyl group provides improved water solubility, while bulky hydrophobic groups 
such as a pyran ring or prenyl, and hydroxyl in B ring decrease water solubility 79. 
 
 
3.2. Lipophilicity 
Lipophilicity is one of the first physicochemical properties to be evaluated in the early phases of a 
drug discovery program and has been correlated with several other physicochemical and PK properties, 
for example, solubility, permeability, plasma protein binding, metabolism, blood-brain barrier (BBB) 
penetration, volume of distribution and clearance. A compound with moderate lipophilicity has a good 
balance between solubility and permeability and is optimal for oral absorption, cell membrane permeation 
in cell-based assays, and is generally good for BBB penetration (optimal distribution coefficient 
logarithm -log D-  ~2). Consequently, it may extensively influence the success or the failure of a drug 
discovery program. In fact, compounds with high lipophilicity have shown an increased risk of attrition 
during the clinical trials. 
Lipophilicity is commonly evaluated by the logarithm of the partition coefficient (log P) of an un-
ionized solute in a biphasic system using the so-called shake-flask method. Different solvent systems 
have been used for estimating this property, but the octanol/phosphate buffer pH 7.4 system remains the 
most common, and mimics, respectively, the biomembranes and the blood in vivo. The determination of 
the log P of a solute in a biphasic octanol–water system by the shake-flask method  is described in the 
OECD (Organization for Economic Co-operation and Development) guidelines for testing chemicals 80. 
The solute is simply partitioned between the two liquid phases of the proposed solvent system in a test 
vessel. Both solvents should be mutually saturated at room temperature (20 to 25 ºC) before the log P 
determination.  After equilibrium and separation, usually achieved by centrifugation, the relative solute 
concentration in each layer is determined using a variety of analytical techniques. These include 
spectroscopic methods, HPLC, GC, thin-layer chromatography (TLC), among others. 
The octanol–water distribution of several hydroxylated and/or methoxylated xanthones was 
systematically investigated in a biphasic octanol–water system and their log P values lie in the range 
2.90–3.80 81. Optical density of the aqueous phase and of the organic phase was measured on a 
spectrophotometer. Stock solutions of compounds (concentration 10–2 M) were prepared in octanol and 
shaken with a known volume of extractant (doubly distilled water saturated with octanol). The aqueous 
phase was acidified with HCl (1 N) to pH 2-3 in order to avoid dissociation for the study of the 
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distribution of compounds containing free phenolic groups. Experiments were conducted with varying 
phase (octanol–water) ratios (1:20, 1:30, 1:40, 1:50, 1:60) to cover a wide range of lipophilicity values, at 
20–22°C 81.  
The octanol–water system has some limitations since it fails to create the anisotropic media that is 
found on biomembranes and encode some important interactions that take place between the solute and 
the membranes. Therefore, other models have been developed such as liposomes and micelles which have 
proved to be advantageous when compared to octanol–water. The lipophilicity of several prenylated and 
pyranoxanthones was determined as the partition coefficient (P) of the solute between buffer (pH 7.4) and 
micelles or liposomes, and calculated without a phase separation 75,82. The tested compounds showed a 
moderate to high lipophilicity. A good correlation between the two models, micelles and liposomes was 
observed, which implies that there is no clear tendency for the tested compounds to increase the affinity 
for either of the membrane models with an increase in hydrophobicity. The results obtained led to the 
observation that micelles can be used as a surrogate for liposomes for the studied compounds with the 
advantage of not having the light scattering limitation (wavelengths below 300 nm) as well as a higher 
applicability and easier preparation 75,82.  
All the pyranoxanthones showed a Log Kp in liposomes and micelles superior to 3 but below the 
critical 5 (upper limit referred in the Lipinski “rule of five”). The presence of a hydroxyl ortho to the 
carbonyl leads to a dramatic increase in the lipophilicity. Considering the relationship between the 
hydroxyl or methoxyl group with the oxygen of the fused pyran ring, the compounds with an ortho 
relationship seem in most of the cases to have a lower partition coefficient than in meta position. 
Comparing the linear with the angular arrangement of the molecule of pyranoxanthones, it can be 
observed that in general, the latter have a less partition coefficient than the former. Regarding the 
presence or absence of the double bond in the fused ring, there is not a clear tendency among the different 
set of compounds 82. 
Considering the effect of ring A (see Fig. 5) substituents on the Kp of compound 12, it was observed 
that chlorine and methyl were associated with an increase in Kp. In the case of the methoxyl, the 
introduction of this group in position 8 did not interfere with the Kp while the introduction in position 10 
was associated with an increase of the Kp. For the hydroxyl group an unexpected result was observed and 
no decrease in Kp was determined. In fact, for assays with micelles, an increase in Kp was observed. 
Considering the analogues of compound 12 with a methoxyl in position 12, it can be observed that this 
substituent was associated with an increase in the Kp. Comparing with the analogues with a different ring 
D orientation, it can be observed that most of the compounds had a Kp near or higher than 4 with the 
chlorine and the diethylamine derivatives representing the compounds that showed a higher Kp 75. 
Among the xanthones tested, pyranoxanthone 13 (Fig. 6) was the most lipophilic 75,82.  
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Fig. 6: Pyranoxanthone (13) with the higher Kp. 
 
HPLC method is also described in the OECD  guidelines for testing chemicals 83. With the 
development of reversed phase HPLC in many laboratories,  readily accessible retention factor of a new 
compound, compared to the standard but time consuming shake-flask method, made the method 
extremely popular and widely used 84. Reversed phase HPLC is performed on analytical columns packed 
with a solid phase containing long hydrocarbon chains chemically bound onto silica. The chemicals are 
retained in the column in proportion to their hydrocarbon-water partition coefficient, with hydrophilic 
chemicals eluted first and lipophilic chemicals last 83. 
Using HPLC methods, the log P values of a series of xanthone derivatives - obtained by cationic 
modification of the free C3 and C6 hydroxyl groups of α-mangostin with amine groups 85 - ranged 
between 5.42 and 15.01. In this study the log P and molecular hydrophobicity parameters were found less 
predictive than pKa for improving the antimicrobial properties of xanthone analogues.  
 
Most solutes are weak bases or acids which become partially ionized when dissolved on water. This 
has raised the need to develop the distribution coefficient (D) which is used to determine the ratio of the 
sum of the concentrations of all forms of the solute (pH dependent mixture of ionized plus un-ionized 
forms) in each of the two phases. The logarithm to the base 10 of the distribution coefficient (log D) is 
normally used to express results 86. 
The log D at pH 7.4 of a set of 40 compounds obtained by propargylation of hydroxyxanthone 
substrates were determined according to the method of Avdeef and Tsinman on a Gemini Profiler 
instrument (pION) by the “gold standard” Avdeef−Bucher potentiometric titration method. Log D values 
were between 0.44-6.0 79. 
 
 
3.3. Acid dissociation constant (pKa) 
It is well known that ionized compounds are more soluble in water than the neutral forms, but less 
permeable. Ionization is determined by the pKa and aqueous pH; thus, pKa has a major effect on PK 
properties. Buffer solutions with different pH values have to be prepared by mixing appropriate volumes 
of the stock solutions and then diluting to ionic strength I = 0.03, which were controlled by calculation 
and by acid–base equilibrium theory. The pH should be measured at 25 °C by a pH meter calibrated in 
advance with standard buffers at the pH range. 
Mangiferin (3) pKa values were determined in aqueous solution by UV–Vis spectroscopic studies 
coupled with nuclear magnetic resonance (NMR) detector.  The NMR study complemented the pKa 
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values assignment and evidenced a hydrogen interaction at C-1 with the carbonyl group. Results showed 
that the proton at hydroxyl in position 1 is the less acidic, assigning the last pKa to this proton. This result 
contrasted with the predicted by the ACD/pKa DB version 5 (Advanced Chemistry Development, Inc., 
Toronto, Ont., Canada, www.acdlabs.com, 2003) that estimated this proton as the most acidic one 87.  
Capillary zone electrophoresis (CZE) method, which relies on measuring the mobility of the solute 
as a function of pH, has been proved to be an effective and convenient technique for determining the pKa 
values being considered as an universal technique for determining pKa values in a wide pH range.  The 
accuracy of pKa values obtained from CZE has been confirmed to be in agreement with those from 
potentiometric methods and, in general, better than those from single chromatographic or 
spectrophotometric methodologies. 25. Compared to spectroscopy, potentiometry, conductivity or other 
techniques, CZE has advantages concerning sensitivity (only small amounts of sample are required), 
analysis time (relatively short), the result is independent of the solute purity (high purity is not necessary), 
it is applicable to samples that are weakly soluble in water (can be performed in aqueous or nonaqueous 
solvents), and the procedure does not require solute measurement or titrant concentrations, but only the 
migration times of solutes 25. Another important advantage of CZE method is that the pKa values of 
solutes based on both their migration times and UV absorbance measured from online spectra can 
determine, when online diode array detection (DAD) is used 25.The pKa values of 10 hydroxylated and/or 
methoxylated xanthones, isolated from herbal medicine Securidaca inappendiculata, have been 
determined by CZE based on linear and nonlinear regression models and the results were confirmed by 
UV absorbance from online DAD  25. The results showed that the precision of the two methods, expressed 
in terms of the acceptable repeatability and reproducibility of the migration time, mobility and pKa 
values, is acceptable 25.  
In another study, prediction of pKa values was highlighted as a new way to improve “hits” for the 
development of membrane-active antibiotics that target drug-resistant pathogens 85. Results showed that 
the antimicrobial activities of cationic xanthone derivatives can be generally predicted based on the pKa 
values of the corresponding amines. Pyrazole and triazol moieties which led to low pKa values reduced 
the antimicrobial activity of the derivatives when compared with the parent compound 85.  
 
3.4. Permeability  
With the development of drug discovery, methods that can screen in vitro permeability of 
compounds rapidly received significant attention. The Caco-2 cells represent a well-known and 
interesting cell culture-based model for enterocytes which has been used in several in vitro bioavailability 
assays to evaluate the intestinal absorption rate of a broad range of drugs. The first report on xanthones 
bioavailability and metabolism was performed using the coupled in vitro digestion/Caco-2 human 
intestinal cell model 88. Optimal bioavailability of α- (4) and γ-mangostin (5) were dependent on 
incorporation into bile salt mixed micelles. In addition, α-mangostin (4) was transported across the apical 
surface of enterocyte-like Caco-2 cells and partially converted to phase II metabolites 37. Both 
unconjugated α-mangostin (4) and its phase II metabolites were effluxed across the basolateral membrane 
suggesting that they were absorbed. Transepithelial transport was enhanced by addition of products of 
lipid digestion in the apical compartment, suggesting that absorption was dependent on the assembly and 
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secretion of chylomicrons. α-Mangostin metabolites also were retro-transported across the apical 
membrane into the simulated gut luminal compartment 37. An HPLC-UV analysis from the in vitro 
permeation assay with Caco-2 cells monolayer was performed to predict the intestinal permeability of 
different xanthonic derivatives (oxygenated, prenylated, xanthonolignoids) 89 which revealed high 
apparent permeability coefficients (Papp) similar to other well absorbed drugs 51.  
Parallel artificial membrane permeability assay (PAMPA) has been applied early in drug 
development. Most drugs are absorbed through passive diffusion across the lipid bilayer membrane of the 
epithelial cells into systemic circulation. The process is driven by concentration gradient. The PAMPA 
assay is designed to measure passive diffusion through an artificial lipid membrane. Permeability 
coefficients of a set of 40 propargylxanthone derivatives were determined using a standard PAMPA 79. 
The results suggested that the trends of permeability of propargylxanthone derivatives are similar to their 
behavior in solubilities (see section 3.1): compounds with smaller frameworks and hydrophilic groups are 
also likely to have better permeability.  
 
3.5. Modulation of ABC Transporters 
ATP-binding cassette (ABC) transporters are present in all cells of all organisms and use the energy 
of ATP binding/hydrolysis to transport substrates across cell membranes. Several membrane proteins 
belonging to the ABC family of proteins act by preventing the absorption of orally ingested or airborne 
xenobiotics or drugs. Among these proteins, P-glycoprotein (P-gp) and multidrug-resistance protein 1 
(MRP1) are the most extensively studied 90,91. These ABC transporters are attractive therapeutic targets 
since their inhibition could overcome multidrug resistance to anticancer drugs while its 
induction/activation could limit the toxicity of substrates such as pesticides. Thus, investigation on ABC 
transporters modulation by xanthone derivatives is not limited to permeability studies and aims mainly 
these pharmacological perspectives.   
 
3.5.1. MRP1 modulation 
MRP1 promotes drug efflux in which is considered phase III metabolism in two possible ways: 
conjugation with glutathione (GSH) or by co-transport with free GSH 92. In the search of compounds with 
cytotoxicity towards cancer cells overexpressing MRP1, Genoux-Bastide et al. 93 studied a library of 
xanthones and compared the results with a well-known activator of massive GSH efflux by MRP1, the 
calcium channel blocker verapamil 94,95. 
The total cellular GSH determination was measured using the enzymatic method described by Tiezte 
96, as modified by Anderson 97 to the microtiter plate. From the library of xanthones evaluated, derivatives 
with more than 40% of GSH efflux scores were investigated to determine their cytotoxicity against a 
sensitive tumor cell line (NCI-H69) and a MRP1-overexpressing human resistant cell line (H69AR/MRP1 
derived from NCI-H69). In order to evaluate if the most active compounds for selective killing of MRP1-
overexpressing resistant cells activity was correlated with MRP1 expression, cytotoxicity of the two best 
compounds was tested on three HEK-293 cell lines, (one with wild-type Pgp, one with ABCG2 and one 
with pcDNA3.3) and on two MDCK2 cell lines (one with wild-type MRP2 and one without it). Since the 
achieved IC50 value was greater than 100 µM to the five cell lines, it allowed to conclude that the 
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analyzed compounds were selective killers of resistant cells overexpressing MRP1 93. Structures of the 
most promising compounds are shown on Fig. 7. 
 
 
 
Fig. 7: Chemical structures of 
xanthones with GSH efflux of more than 40%.  
 
 
The results allowed inferring that cell death was not dependent just by the GSH efflux, since some 
xanthones induced efflux of GSH by more than 50% and show no significant cytotoxicity towards the 
tested cell line. Therefore, the selective cytotoxicity presented by compound 17, Fig. 7 is more likely due 
to a MRP1 activation followed by apoptosis through an acceleration of GSH efflux from the cell 93. 
 
3.5.2. P-gp modulation 
P-gp is responsible for the transmembrane transport of neutral or positively-charged hydrophobic 
substrates, namely anticancer agents. Over the past decades, this target has drawn a lot of interest in 
several research areas, such as Medicinal Chemistry and Toxicology. First, because its inhibition can lead 
to increase cytotoxicity and therefore increase therapeutic efficacy of anticancer agents and, on the other 
hand, due to its broad substrate specificity and ubiquitous presence in excretory and barrier tissues, its 
activation can play a crucial role in limiting the absorption and distribution of toxic xenobiotics 98-100. 
In our group, to improve the efficacy in sensitizing resistant P-gp overexpressing cell lines, 
(thio)xanthones P-gp modulators were obtained based on structure-based design approaches 101. The 
methods applied to validate a library of dual inhibitors of P-gp and tumor cell lines are summarized in 
Table 6 101. 
 
Table 6: Methods applied in biological studies of a library of thioxanthones. 
Aim Methods Description 
Cell growth study 
Sulphorhodamine-B assay 
Serial dilutions of tested compounds were 
applied on K562 and K562Dox cell lines to 
determine de GI50 values. 
Trypan blue exclusion assay 
Investigation of cellular viability in MRC-5 cell 
line, using the compounds in their GI50 
concentration achieved to the K562 cell line. 
P-gp modulation study 
Rhodamine-123 accumulation 
assay 
K562 and K562Dox cell lines were incubated 
with the thioxanthones and rhodamine-123, 
followed by flow cytometry analysis. 
Compound R1 R2 R3 R4 
14 OH CH3 OCH3 H 
15 OH OH OCH3 H 
16 OH OH H H 
17 OH OH H OCH3 
18 OH OH H CH3 
19 OH OH H OH 
20 OH OCH3 H OCH3 
21 OCH3 O-Bz H OCH3 
22 OH OH H NH-COCF3 
23 OH OH H NH2 
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ATPase assay 
ATPase activity of P-gp was determined using 
the luminescent ATP detection kit (P-gp-Glo 
Assay Kit, Promega, Germany). The remaining 
ATP was detected as a luciferase-generated 
luminescent signal. 
Sulphorhodamine-B assay 
Evaluation of the ability of thioxanthones to 
decrease doxorubicin GI50 in K562 and 
K562Dox cell lines. Serial dilutions of tested 
compounds and a solution of doxorubicin were 
applied on K562 and K562Dox cell lines to 
determine de GI50 values. 
K562 and K562Dox cell lines – human chronic myelogenous leukemia cell line and doxorubicin-induced P-gp 
overexpression K562 cell line; GI50 – drug concentration that exerts a growth inhibition rate to 50% of the maximum 
rate; MRC-5 cell line – human fetal lung fibroblast-like cell line; ATPase – adenosine triphosphatase; P-gp – 
permeability glycoprotein. 
 
In this study, both inhibitors and activators of P-gp were found and in Fig. 8 are highlighted the hit 
compounds concerning P-gp noncompetitive and competitive inhibitors 101. 
 
 
 
Fig. 8: Thioxanthone noncompetitive 24 and competitive 25 inhibitors of P-gp. 
 
Further studies to evaluate the selectivity profile of thioxanthones as inhibitors of MDR were 
performed, by studying their interaction with other ABC transporters, namely MRP1, MRP2, MRP3 and 
BCRP. Another important assessment was the evaluation of the interaction of thioxanthones with P450 
3A4 (CYP3A4), as well as the prediction of their binding conformations and metabolism sites 102. The 
results allowed to conclude that compound 25 (Fig. 8) is a promising multi-target inhibitor of P-gp, 
BCRP and MRP1. On the other hand, 1-[2-(diethylamino)ethyl]amino-4-propoxy-9H-thioxanthen-9-one 
(26, Fig. 9) is a multi-target inhibitor of P-gp, BCRP, MRP1 and MRP3.  
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Fig. 9: Multi-target inhibitor of P-gp, BCRP, MRP1 and MRP3 thioxanthone 26. 
 
Nowadays, strategies to increase P-gp expression and/or activity are considered as a potential 
detoxification pathway to prevent the harmfulness mediated by toxic P-gp substrates, by reducing their 
intracellular accumulation 100,103,104. Thioxanthones that revealed an effect compatible with P-gp 
activation were further validated as P-gp activators for their effect in protecting against Caco-2 cells from 
PQ-induced toxicity 105. A library of dihydroxylated xanthones (27-30, Fig. 10) was also evaluated on 
their effect towards P-gp activation and induction. Table 7 shows the methods applied in these 
investigations 100. 
 
Table 7: Methods applied for the study of the effect of (thio)xanthones on P-gp. 
Aim Method 
Cytotoxicity evaluation 
MTT reduction assay 
Neutral red uptake assay 
P-gp expression evaluation Flow cytometry 
P-gp transport activity 
evaluation 
Rhodamine-123 efflux assay in Caco-2 cells pre-exposed 
to xanthones for 24h 
(Flow cytometry) 
Rhodamine-123 efflux assay in Caco-2 cells in the 
presence of xanthones 
(Flow cytometry) 
P-gp ATPase activity 
evaluation 
ATPase screening assay 
Paraquat cytotoxicity 
evaluation 
Neutral red uptake assay 
P-gp – permeability glycoprotein; ATPase – adenosine triphosphatase; Caco-2 cells – 
human epithelial colorectal adenocarcinoma cell line. 
 
Fig. 10 shows structures of the tested dihydroxylated xanthones. The most active compound was 30, 
followed by 27, 29, 16, and 28 was the least active. The overall results allowed to conclude that a 
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hydroxyl group on position 3 of the xanthonic scaffold seems to increase the P-gp activation, while when 
in position 1, the activation was decreased 100.  
 
  
Fig. 10: Dihydroxylated xanthones tested for their P-gp activation/induction activity. 
 
3.6. Plasma protein binding  
For studying the interaction between small molecules as drugs and proteins, several techniques have 
been applied, such as electrochemistry, chromatography, NMR and spectral analysis. Spectral analysis is 
applied widely because of the easy operation, low cost, and abundant theory foundation 106. 
A simple HPLC method with fluorimetric detection for the determination of the free DMXAA (2, 
Fig. 1) concentration in human plasma was reported 62. Sample preparation involves the ultrafiltration of 
plasma and extraction with an acetonitrile:methanol mixture. The HPLC method has been used for the 
analysis of preclinical studies 62. DMXAA (2) exhibited high plasma protein binding which was 
concentration-dependent and with significant variation between animal species 62. 
Binding experiments with BSA were performed for mangiferin (3) 106. BSA exhibits an intrinsic 
fluorescence when excited at 280 nm, which gives valuable information regarding both the 
macromolecule structure and dynamic complex state 107. In the fluorescence assays is possible to observe 
a continuous decrease in tryptophan quenching of BSA with the binding. Mangiferin (3, Fig. 2) strongly 
absorbs wavelengths in the UV range due to its glycosidic residue at position 2 107. Complex formation is 
evident by both the hypochromic and bathochromic effects in the presence of BSA, where the 
bathochromic effects can be attributed to structural changes that are induced by the bound ligand 107. 
Synchronous fluorescence spectra indicated that there are conformational changes in the polypeptide 
backbone of BSA upon a ligand binding 106. In a different study performed by cyclic voltammetry, results 
indicated that there is an irreversible charge transfer between mangiferin (3) and BSA that is modulated 
by diffusion on the electrode surface, where two electrons are transferred 107. 
 
3.7. Stability  
 
Stability of drug conjugates - as metabolic and chemical stability- is a matter of great concern to be 
investigated during the drug development process, once it affects the safety and efficacy of the final drug 
product 108, being compounds containing highly reactive functional groups less stable 109. The methods 
generally used to assess the stability result of guidelines published by ICH (International Conference on 
Harmonization). This guidance state the requirement of stability testing data to understand how the 
quality of a drug substance and drug product changes with time under the influence of environmental 
Compound R1 R2 R3 R4 R5 
27 H H OH OH H 
28 OH OH H H H 
16 OH H OH H H 
29 H OH OH H H 
30 H H OH H OH 
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factors and specific experimental conditions 108. Investigations on stability include titration, 
spectrophotometric and chromatography methods. They are relatively inexpensive and easy techniques, 
being HPLC the most commonly used. To study stability it is necessary to analyze the structure and its 
physicochemical properties to understand which compounds can derive from the degradation of the drug 
candidate and identify them by a simple and reproducible chromatographic method 22,110. 
Studies performed with xanthone derivatives in biological and in non-biological samples considered 
different stress factors as highlighted in the following sections. 
 
 
 
3.7.1. Stability in biological samples 
 
3.7.1.1. Extreme temperatures stability 
 The study of stability in extreme temperatures involve cycles of freezing at -20ºC for hours to days 
and thawing at room temperature for hours, repeating three times. These kind of studies were developed 
for some xanthone derivatives, namely mangiferin (3) 27,111,112, neomangiferin (31, Fig. 11) 27, gambogic 
acid (6) 44, and its major metabolite 10-hydroxygambogic acid (10-OHGA) 113, polygalaxanthone (32, 
Fig. 11) 114, sibiricaxanthone F (8) 48, α- (4) and γ-mangostins (5) 35, and DMXAA (2) 69.. Analysis were 
conducted with comparison with QC (Quality Control) samples replicates, where a standard solution was 
added to a blank matrix sample submitted to the same conditions 27,44,112. Afterwards, the samples were 
analyzed in LC-ESI-MS/MS 27,35,69, UFLC-MS/MS 112 or HPLC-UV 44. Results obtained revealed that 
these compounds are stable 27,44,69,111,113,114 or did not exhibited significant degradation 7,35,112 under the 
studied conditions. 
 
Fig. 11: Strucures of neomangiferin (31) and polygaloxanthone (32). 
 
3.7.1.2. Short-term stability 
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The short- term stability usually corresponds to the storage time of samples before analysis from a 
few hours (i.e. 4h) to 24h at room temperatures 10,35,44,111,113-115. Analysis were conducted with comparison 
with QC samples and analyzed in LC-ESI-MS/MS or HPLC-UV as mentioned in freeze/thaw studies. 
A polysulfated derivative of mangiferin (33, Fig. 12) was submitted to stability evaluation in human 
plasma for 3h at 37ºC and showed no significant difference from the standard solution (Scheme 3) 116. 
Also, DMXAA (2) showed stability in human plasma at 37 ◦C (in water bath) for at least 2 h through LC-
MS/MS analysis 69. 
 
 
Fig. 12: Structure of the polysulfated derivative of mangiferin (33). 
 
For assessing the stability of biological samples there is necessary to a pre-treatment process before 
analysis. To fulfill such purpose, some stability studies were performed by leaving prepared samples at 
4ºC for 8 h 112,114. Other studies were conducted storing pre-treated samples in the auto-sampler for 4h 111, 
12h 27,35 at room temperature or 6 days at 2-8º C before re-injection in order to control reproducibility 69. 
No significant degradation occurred when the extracted samples were kept in the autosampler at room 
temperature for 12 h 27 or 6 days at 2-8º C 69. 
 
 3.7.1.3. Long-term stability 
 
For the assessment of long-term stability, samples of α-mangostin (4) and γ-mangostin (5) were 
subjected to a storage time of 21 days 35, for one month to samples of sibiricaxanthone F (8) 7 and for two 
months to samples of 10-OHGA (hydroxylated derivative of gambogic acid in position 10) 113 at -20º C 
and no significant alterations after HPLC MS/MS 7,35 or LC-ESI-MS 108 analysis were observed. 
 
3.7.2. Stability in non-biological samples 
  
3.7.2.1. Short-term stability 
Gambogic acid (6, Fig. 4) was dissolved in different extraction solvents and the sample solutions 
were stored for a week before being tested and analyzed by HPLC. The stability of gambogic acid (6) was 
dependent of the solvent used, once when extracted and stored in methanol appeared another peak in the 
chromatogram, further identified corresponding to10-OHGA 117. 
 
3.7.2.2. Long-term stability 
Polysulfated xanthone 33, analyzed by HPLC-DAD, was found to be chemically stable for 15 days 
under different temperature storage conditions, namely room temperature, 4º C and -20º C 116.  
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3.7.2.3. Accelerated stability 
Forced degradation of α-mangostin (4) (Fig. 3) was carried out under thermolytic, photolytic, 
acid/base hydrolytic, and oxidative stress conditions and the analysis was performed in HPLC-UV 118. 
Thermal (in a controlled-temperature oven at 80º C for 3 h) and photo-degradation (under UV at 254 and 
366 nm for 6 h) were performed in solid state. For hydrolytic and oxidative degradation, solutions were 
prepared by dissolving α-mangostin (4) extract in a small volume of methanol, and later dropped with 3% 
hydrogen peroxide, 3N HCl, or 3N NaOH solution and heated at 80º C for 3 h. All sample solutions used 
for for acid/base hydrolysis and oxidative stress were kept in a dark to prevent the effect of light. It was 
found that α-mangostin (4) was stable under light, heat, and basic hydrolytic conditions. Nevertheless, the 
α-mangostin (4) demonstrated decomposition in acidic and oxidative conditions.  
 
3.7.2.4. pH stability 
To assess pH stability of polysulfated xanthone 33 the following buffers were used: HCl (pH 1.0), 
sodium acetate (0.05 M, pH 5.0), potassium phosphate (0.1 M, pH 6.8), PBS (pH 7.4), and sodium boric 
acid (0.05 M, pH 9.1). Solutions were left at 37º C for further analysis in HPLC-DAD at 0, 1, 2 and 3 h. 
This compound did not degrade at the range of pH values selected 116. 
Regarding mangiferin (3), different solutions were prepared at acid, neutral and basic pH and 
analyzed after 24 h, revealing that a small variation within the experimental interval through UV/Vis 
spectroscopy occurred. These data leaded to the decision to not use mangiferin (3) solutions for more than 
12 h after preparation in order to assure they will remain stable 119. 
 
3.8. Clearance 
The lack of data concerning bioavailability of interesting xanthone derivatives impelled the study of 
PK parameters including clearance which evaluates the rate of a compound that is cleared from the blood 
after administration. For mangiferin (3, Fig. 2) 27,120,121, neomangiferin (31) 27, cudratricusxanthone B (9) 
43 and α-mangostin (4) 37 some in vivo studies have been carried out in rats after intravenous and/or oral 
administration. Blood samples were collected in different time periods to achieve a concentration versus 
time relationship. Samples were centrifuged to obtain plasma and after that pre-treated to eliminate 
proteins for chromatographic analysis; further PK parameters were calculated using a software 27,39,120. 
Regarding to mangiferin (3) 27,120,121 and cudratricusxanthone B (9) 43 these compounds have a low rate of 
clearance but neomangiferin (31) being a more hydrophilic compound has a higher clearance 27. Also 
differences in clearance may be found after an oral or intravenous treatment with mangiferin (3) 120.  
 
4. Xanthone derivatives metabolism 
Genetic aspects of both drug metabolism and susceptibility to drug toxicity have become widely 
assessed in an early stage of drug development aiming to diminish the attrition rate during development 
phases due to poor PK 17,122,123. Further, the study of the metabolic fate of a compound is interesting not 
only in a bioavailability and in a toxicity perspective, but also to discover possible active metabolites and 
lead compounds for optimization 124,125. 
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There are different approaches to assess drug metabolic profile that could be categorized in three 
major models: in silico, in vitro and in vivo 122. Regarding to in vitro models, beyond other 
methodologies, it is possible to assess drug metabolism (phase I and II) with rat and human liver 
microsomes and with recombinant isoforms of CYP450 enzyme (taking into consideration genetic 
polymorphisms). Also, it is important to search for glutathione conjugates allowing to search for 
electrophilic metabolites 122. In the presence of an inhibitor of CYP450 it is also possible to understand 
potential drug-drug interactions 17,122. Additionally, it is important to understand the metabolism by the 
intestinal flora that could be assessed in vitro, regarding a future oral bioavailability 30,42,126.  
The study of drug metabolism with in vivo models usually is conducted by analyzing plasma, urine 
and feces. The investigation of bile appears to be interesting in order to complement the study of the main 
metabolic and disposition pathways in animals. It allows metabolic profiling across species and offers 
insight into the extent of in vivo formation of metabolites 122. Usually the analysis, metabolites detection 
and identification, is made through LC-MS/MS 122. 
Besides diverse and potential activities of xanthone derivatives have been well documented 1,4-6,15,16 
the understanding of their metabolism is an area in exploration to realize the possible metabolic pathways 
and characterize their metabolites 30,127. Pre-clinical metabolism studies of xanthones have been carried 
out through in vitro (Table 8) and in vivo models (Table 9) in a quantitative and comparative way. 
Further, it is valuable to take into account the knowledge of the major CYP450 enzymes involved in the 
metabolism of potential drug candidates to predict possible drug-drug interactions, as well as genetically 
based individual variation in drug metabolism. In vitro models (Table 8) with rat and human liver 
microsomes and CYP450 isoforms allowed to discover and to identify metabolites of DMXAA (2), 
mangiferin (3), α-mangostin (4), gambogic acid (6), and other natural xanthone derivatives. 
 
 
Table 8: In vitro models carried out for xanthones metabolism studies. 
PK study Model  
Sample  
Pre-
preparation 
Chromato-
graphic 
method 
Ref. 
To investigate 
intestinal flora 
metabolism of 
mangiferin (3)   
Rats intestinal flora homogeneized 
with anaerobic cultural solution. 
Filtration. Incubation with mangiferin 
(37 oC. Reaction terminated by 
cooling them at 4º C, after 2, 6, 10 
and 24 h). 
SPE column. 
Dryness by 
nitrogen gas. 
Dissolution in 
methanol. 
Centrifugation. 
LC-ESI-IT-
MS 
30 
To investigate 
phase II 
conjugation of 3 
Subcellular rat liver fractions 
(microsomal and cytosolic). 
Glucuronidation –microsomes (with 
UDPGA, 37 oC, 60 min. Reaction 
terminated with ice-cold methanol). 
Sulphation – cytosolic fraction (with 
PAPS, same conditions as above). 
Enzymatic hydrolysis of 
glucuronidated metabolites (37º C, 
120 min). 
Centrifugation. 
Extraction with 
methylene 
chloride and 
centrifugation. 
Dryness by 
nitrogen gas. 
Dissolution in 
water followed 
by SPE column. 
HPLC-UV/Vis 29 
To study the 
metabolism of α-
mangostin (4) by 
different human 
Human cell cultures: THP-1, HepG2, 
Caco-2 HTB-37, HT-29 and MDM 
(37 o C, 95% humidity and 5% CO2, 
24 h). Medium and cells were 
w/i * RP-HPLC-UV 33 
26 
 
cells’ types in 
normal and pro-
inflammatory 
environments 
collected. Previously treatment with 
LPS for the pro-inflammatory 
environment. 
To investigate the 
metabolism of 
gambogic acid (6). 
To identify the 
major CYP450 
isoform involved 
the metabolism and 
potential DDI 
Rat liver microsomes (with NADPH, 
37 oC, 30 min. Reaction was 
terminated with HCl 1 mol/L). For 
DDI the same study was performed 
with chemical inhibitors. 
Extraction. 
Centrifugation. 
Dryness. 
Dissolution in 
mobile phase. 
HPLC-UV 128 
To clarify the final 
disposition and 
metabolic profile of 
6 
Liver microssomes: 
- NADPH-dependent CYP450-
mediated and non-P450-mediated 
metabolism 
- UDPGA-dependent UGT-mediated 
metabolism 
- GSH-dependent non-GST-
mediated metabolism 
Reactions terminated with ice-cold 
acetonitrile. 
Centrifugation. 
Dryness by 
nitrogen gas. 
Dissolution in 
mobile phase. 
LC-MS/MS 127 
To characterize 
metabolism and 
predict possible in 
vivo metabolites of 
sibiricaxanthone F 
(8) and aglycone  
. 
i) Rat intestinal flora (homogeneized 
with culture medium). 
Centrifugation. Incubation at 37 oC, 
for 0.17, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 
18 or 24 h. Reactions were 
terminated with ice-cold n-butanol). 
ii) Microssomal proteins (with 
NADPH, 37 oC, 60 min. Reaction 
terminated with ice-cold methanol). 
iii) Glucuronidation – Rat and 
Human liver microsomes (with 
UDPGA, 37º C, 15 min. Reaction 
terminated with ice-cold methanol). 
i) Internal 
standard was 
added. 
Centrifugation. 
Dryness by 
nitrogen gas. 
Dissolution in 
methanol and 
filtered (0.45 
µm membrane). 
 
ii) and iii) 
Centrifugation. 
 
HPLC-EMS-
IDA-EPI 
42 
To identify the 
CYP450 isoform 
responsible for 
metabolism and 
interindividual 
variability of 
DMXAA (2) 
HLM and cDNA-Expressed Human 
Microsomes containg recombinant 
human liver CYP isoforms (with 
NADPH, 37 oC, 40 min. Reaction 
terminated with ice-cold 
acetonitrile:methanol (3:1)). 
Addition of 
internal 
standard. 
Centrifugation. 
Dryness by 
nitrogen gas. 
Dissolution with 
mobile phase. 
HPLC-SF250 
flourescence 
detector 
59 
To study the 
metabolism of 2 by 
Caco-2 cells 
Human intestinal Caco-2 cells (37º C 
in triplicate. Medium aliquots were 
collected at 0, 5, 10, 15, 20, 30 and 
60 min. At the end cells were 
harvested and digested with 0.02N 
HCl/methanol (1:1). 
w/i * 
HPLC-SF250 
flourescence 
detector 
129 
To study the 
metabolism and 
DDI of mangosteen 
extract 
Pooled HLM25 and recombinant 
CYP450 supersomes (with NADPH, 
37 o C, 20 min. (HLM) and 0, 5, 10, 
15, 30 and 45 min (CYP450). 
Reaction terminated with ice-cold 
acetonitrile). 
Addiction of 
internal 
standard. 
Centrifugation. 
LC-MS/MS 130 
To illustrate 
metabolic 
pathways of 1-
hydroxyl-2,3,5-
Pooled HLM and recombinant 
CYP450 isoforms (with NADPH, 37 
oC, 60 min, 800 rpm. Reaction 
terminated with ice-cold acetonitrile). 
Addition of 
internal 
standard. 
Extraction with 
LCMS-IT-
TOF  Isolation 
of metabolite 
with by 
47 
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trimethoxy-
xanthone (HM-1) 
purified from 
Halenia elliptica 
D. Don. 
To identify 
CYP450 isoforms 
responsible for the 
metabolism and 
potential DDI 
For DDI the same study was 
performed with chemical inhibitors. 
ethyl acetate. 
Centrifugation. 
Organic layer 
dried by 
nitrogen gas. 
Dissolution in 
methanol. 
 
preparative 
HPLC and its 
identification 
by 1H NMR 
and 13 C 
NMR. 
To study Phase I 
metabolism of 
Xanthones isolated 
from Halenia 
elliptica D. Don 
Rat liver microsomes (with NADPH, 
37o C, 60 min. reaction terminated 
with ice-cold acetonitrile). 
Centrifugation. 
Extracted with 
ethyl acetate. 
Dryness by 
nitrogen gas. 
Dissolution in 
methanol. 
LCMS-ESI-
IT-TOF 
41 
SPE - solid phase extraction; LC – liquid chromatography; ESI – electrospray ionisation; IT – ion trap; MS – 
mass spectrometry; UDPGA - uridine 5'-diphospho-glucuronic acid; PAPS – phosphoadenylylsulphate; THP-
1 - monocyte-like leukemia; HepG2 - hepatocelular carcinoma; HTB-37 - colorectal adenocarcinoma cells 
that spontaneously differentiate to enterocyte-like phenotype; HT-29 - colorectal adenocarcinoma; MDM - 
monocyte-derived macrophage; LPS – lipopolysaccharides; RP- reversed phase; CYP450 – cytochrome 
P450; DDI – drug-drug interaction; NADPH - nicotinamide adenine dinucleotide phosphate; UGT - Uridine 
5'-diphospho –glucuronosyltransferase; GSH – glutathione; GST - glutathione S-transferase; EMS – 
enhanced mass spectrum; IDA – information dependente acquisition; EPI – enhanced product ion; HLM – 
human liver microssomes; cDNA – complementary DNA; SF - synchronous fluorescence; TOF – time of 
light. 
* w/i – without information. 
 
Further, in vivo models (Table 9) allowed to attain more complete insights of what occurs to 
xanthones during metabolic phases as well as they take in consideration other PK properties 32,126. Also in 
vivo assays enable the discovery confirmation of some hypothetic metabolites identified through in vitro 
models as it occurred for gambogic acid 6 127,128. In the case of mangiferin (3) the aglycone metabolite 
was detected in in vitro and in vivo models due to intestinal flora activity 30,126. 
 
Table 9. In vivo models carried out for xanthones metabolism studies. 
PK study Model Samples Sample Pre-preparation 
Chroma
to-
graphic 
method 
Ref. 
To study the 
metabolism of 
mangiferin (3) 
SD rats. 
Single dose of 
200 mg/kg of 
mangiferin by 
oral gavages. 
Urine and faeces 
0-48h period. 
Blood samples via 
angular vein of 
one hour period 
from 1-11h. 
Organs (heart, 
liver, kidneys, 
spleen, lung) and 
contents of 
intestinal tract at 
2, 4, 7 and 10h. 
Blood in heparinized Eppendorf was 
centrifuged obtaining plasma. 
Organs were weighted and 
homogeneized with PBS buffer. 
Centrifugation. 
Contents of intestinal tract were diluted 
with saline solution. 
All samples were stored at -80 o C. 
Urine, tissue and intestinal homogenates 
were pre-treated in a SPE column. 
Faeces were extracted with methanol. 
Plasma was precipitated with 
acetonitrile:acetic acid (9:1) and 
centrifuged. 
All extracting solutions were dried by 
LC-ESI-
IT-MS 
30 
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nitrogen gas and reconstituted in 
methanol. 
To study the 
metabolism of 
3 
Conventional 
rats, pseudo-
germ-free rats, 
STZ-induced 
diabetic rats. 
Single dose of 
mangiferin 
400 mg/kg by 
oral 
administration
. 
Blood samples 
were collected via 
the angular vein at 
20 min, 40 min, 
70 min, 2, 3, 4, 5, 
6.5, 8, 9.5, 11, 13 
and 24h. 
Urine and feces 
were collected 
during the period 
of 0-48h. 
Samples were pre-treatment according to 
the method described by Liu et al., 2011 
(1st entry). 
HPLC-
DAD 
126 
To isolate and 
identify 
metabolites in 
rat urine of 3 
SD rats. 
Single dose of 
mangiferin 
120 mg/kg by 
oral 
administration
. 
To isolate the 
metabolites - 
Urine samples 
were collected at 
times of 6, 12, 24, 
30, 36, 48 and 
60h. 
For the 
cumulative study 
- Urine samples 
were collected at 
times of 1, 2, 4, 6, 
10, 12, 24, 36, 48 
and 60h. 
Metabolites isolation - Urine samples 
were concentrated. Residues were 
suspended in methanol. The supernatant 
was removed and evaporated to dryness, 
then the residue was dissolved in water 
and partitioned with n-butanol three 
times and then extracted with D101 
(H20/EtOH) and Sephadex LH-20 
(MeOH:H20; 8:2). After that eluted 
fractions were submitted to a silica gel 
chromatography column (cyclohexane-2-
propylalcohol system). Finally a semi-
preparative HPLC was performed. 
HPLC-
UV/Vis 
115 
To investigate 
conjugates of 
α-mangostin 
(4) 
 
Athymic 
Balb/c nu/nu 
mice – HT-29 
colon cell 
xenografts 
model. Diet 
with 
900mg/kg of 
α-mangostin 
for two weeks. 
Samples of liver, 
tumor, blood and 
feaces. 
Clotted blood was centrifuged to isolate 
serum – storage at -80 oC. 
Samples of liver, tumor and feaces were 
weighted and homogeneized in ice-cold 
PBS. Acetonitrile was added to aliquots, 
and centrifuged. Supernatant was dried 
under nitrogen gas. Film was re-
solubilized in acetate buffer (pH 5.5) and 
incubated at 37 oC in the absence or 
presence of glucuronidase/sulphatase 
mixture from Helix pomatia. SPE using 
C18 cartridges. 
HPLC-
DAD and 
HPLC-
MS. 
32 
To study the 
metabolism of 
gambogic 
acid (6) and 
identify 
metabolites in 
rat bile 
SD rats with a 
bile cannula. 
6.0 mg/kg of 
GA was 
injected into 
the vena 
caudalis. 
Bile was collected 
on ice during 12h. 
Bile samples were acidified with 0.1% 
H3PO4 solution and extracted. Dryness 
by nitrogen gas. The residue was 
dissolved in mobile phase and 
centrifuged. 
HPLC-
UV/Vis, 
LC-
ESI/MS, 
LC-
NMR 
46 
To clarify the 
final 
disposition 
and metabolic 
profile of 6 
SD rats. IV 
administration 
of 4 mg/kg of 
GA through 
tail vein. 
Blood samples 
were collected 
from tail vein in 
heparinized tubes 
at 0.033, 0.067, 
0.15, 0.3, 0.75, 1, 
2, and 4h after 
administration. 
Bile samples were 
collected through 
canulla during 
24h. 
Urine and feaces 
samples were 
Plasma samples were extracted. The 
organic layer was separated and 
evaporated under stream of nitrogen in a 
water bath of 40º C. The residue was 
reconstituted in mobile phase. 
Fecal samples were homogeneizedin 
acetonitrile:water (5:5) and centrifuged 
(3000g, 10 min) after ultrasonication for 
10 min. the supernatant was filtered 
through precut membranes (0.45 µm). 
the filtrate was centrifuged and extracted 
as described for plasma samples. 
LC-
MS/MS 
127 
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collected during 
24h. 
To identify 
major 
constituents 
of Zhimu-
Huangqui 
Herb-pair 
extract and 
their 
metabolites in 
rat urine 
18 male SD 
rats. Single 
dose treatment 
via oral 
administration
. 
Blood samples 
collected at 0.5, 1, 
2, 4, 6 and 8 h 
from the 
abdominal aorta. 
Urine samples 
collected for 24 h. 
Blood was centrifuged (12000g, 10 min). 
Aliquots from both plasma and urine 
were loaded on a SPE cartridge, washing 
it with water and eluting with methanol. 
The eluted solution was evaporated 
under nitrogen gas, 37 oC, and residue 
was reconstituted in methanol. 
 
LC-ESI-
MS 
31 
SD - Sprague-Dawley; PBS - Phosphate buffered saline; LC – liquid chromatography; ESI – electrospray 
ionisation; IT – ion trap; MS – mass spectrometry; STZ – streptozotocin; DAD – diode array detector; 
HT-29 - colorectal adenocarcinoma; GA – Gambogic Acid. 
 
Mass spectrometry was found to be crucial in the identification of putative metabolites in both in 
vitro and in vivo analysis. For analysis with LC there is a need to perform samples pre-preparation what 
usually involves protein precipitation, centrifugation and extraction with an organic solvent, afterwards 
lead the extract to dryness and dissolution in an appropriate solvent or in the mobile phase to be used in 
the analytical process. Also, it could be used a SPE column with methanol extraction to pre-treat samples, 
but when mangiferin (3) was the analyte this method revealed as a setback once an extremely low amount 
of mangiferin was detected by HPLC-DAD and LC-MS analysis 29. In order to investigate the conjugated 
metabolites is important to consider the use of glucoronidase and/or sulphatase to detect their presence 
[30].  
These metabolic studies gave new insights of hypothetic metabolic pathways of the above 
mentioned xanthone derivatives namely mangiferin (3) and gambogic acid (6), once they could be 
metabolized by a variety of biochemical routes, including oxidation, hydration, demethylation, 
glutathionylation, glucuronidation, and glucosidation depending on the xanthone scaffold moiety; some 
examples are represented in Fig. 13 115,127. These findings, from assays with intestine and liver of rats, 
provide information on the major metabolic soft spot of different xanthone derivatives, which is not only 
useful in the future human metabolic study of these compounds but also for other xanthones analogues 
127. 
 
Fig. 13. Putative metabolic soft spots for Gambogic Acid (6) and Mangiferin (3). 
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5. Drug candidate DMXAA (5,6-dimethylxanthenone-4-acetic acid or ASA404 or Vadimezan): a 
case-study 
A notable example among the large number of natural and synthetic xanthone derivatives is 
DMXAA (2), a simple carboxylated xanthone (5,6-dimethylxanthenone-4-acetic acid or ASA404 or 
Vadimezan) 1,14. This compound has attracted scientific interest due to its excellent pharmacological 
profile since its discovery 131.  
Several reviews have been devoted on DMXAA (2), focusing mainly on its antitumor activity 132-141. 
DMXAA (2) is a novel tumor vascular-disrupting agent discovered in a structure-activity relationship 
study involving a series of xanthenone-4-acetic acids related to the parent drug flavone acetic acid 131. It 
was selected as a clinical candidate from several xanthone and flavone derivatives, based on its superior 
potency and activity against solid murine tumors. Although its molecular target(s) is(are) not yet known, 
the mechanism of action as well as toxicological and pharmacological profiles are remarkably different 
from most conventional cytotoxic drugs. DMXAA (2) reveals immune modulatory activities inducing 
cessation of tumor blood flow and rapid vascular collapse, leading to ischemia and tumor necrosis 142,143. 
The anti-vascular and immune-modulating effects of DMXAA (2) have been attributed to its ability to 
induce a panel of cytokines, particularly tumor necrosis factor (TNF)-α 123,144-150, interferons (IFNs) 123,151-
154 and interleukins (ILs) 152. It also possesses inductive effects in serotonin 155-157, nitric oxide (NO) 
155,158,159, nuclear factor κB (NF-κB) 145,151,160, and apoptosis of endothelial cells of tumor blood vessels 161-
163. DMXAA (2) has additional antiangiogenic effects 153, and the ability to promote an influx of 
macrophages 164 and neutrophils 165 into the tumor. All these effects may contribute to its antitumor 
activity. 
Interestingly, DMXAA (2) interacts productively with radiotherapy 166-169, immunotherapy 170,171, 
radioimmunotherapy 172,173, photodynamic therapy 174,175, antibody-directed enzyme prodrug therapy 176, 
hyperthermia 169,177, and several drugs, such as chemotherapeutic 178,179, bioreductive cytotoxic 180,181, non-
steroidal anti-inflammatory 182 and thalidomide 183,184.  
DMXAA (2) has been evaluated in Phase I/II clinical trials as a single agent 63,71,185,186 and in 
combination with standard chemotherapy agents 187-191 in patients with advanced cancer. In DMXAA (2) 
plus chemotherapy studies, an improvement of tumor response, median time to disease progression, and 
median overall survival were observed, in both patients with squamous and nonsquamous non-small-cell-
lung cancer (NSCLC) 187-189. These promising clinical studies led to, large-scale, randomized Phase III 
placebo-controlled trial of DMXAA (2) with or without paclitaxel and carboplatin in NSCLC 3. It is 
important to highlight that DMXAA (2) was the first of its class to enter Phase III trials. Although, 
normally well tolerated, the addition of DMXAA (2) to paclitaxel and carboplatin failed to improve 
frontline efficacy, indicating a lack of utility 3. Consequently, Phase III trials were stopped 192.  
The future clinical development of DMXAA (2) as an anticancer drug is currently uncertain, 
however additional efforts aimed to identify analogues with greater activity are under investigation 193,194. 
Moreover, while originally developed as an antitumor agent, alternatively other activities have been 
described for DMXAA (2), namely antiplatelet and antithrombotic 195, or even antiviral 196 (Fig. 14).  
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Fig. 14. Timeline of the most important developments for DMXAA (2). 
 
The distribution-metabolism-elimination profile and PK properties of DMXAA (2) have been 
extensively investigated, by in vitro and in vivo studies using different species of animals and humans 
138,197. All those features will be emphasized in the next section. 
 
5.1. Distribution 
DMXAA (2) was extensively bound in plasma from various species, with concentration-dependence 
and considerable interspecies differences 56,57,62,66,198. For example, the unbound fraction of DMXAA (2) 
(500 µM) was 2.07 ± 0.23 (human), 4.61 ± 1.10 (mouse), 2.59 ± 0.32 (rat) and 2.02 ± 0.48 % (rabbit); 
with DMXAA (2) concentrations ≥ 1000 µM the unbound fraction in the plasma from all species 
increased significantly 66. Considerable alterations in DMXAA (2) distribution into blood cells also 
occurred with increasing concentrations of DMXAA (2). For example, the human blood:plasma 
concentration ratio (CBL/Cp) of DMXAA (2) was 0.673 ± 0.103 over the range 50-1000 µM, but 
increased significantly at higher concentrations of DMXAA (2) 66.  
Plasma binding of DMXAA (2) is also altered by the environment of disease, since in plasma from 
cancer patients there was no significant relationship between bound:free DMXAA (2) concentration ratio 
and albumin concentration; in opposition, in healthy human plasma a linear correlation was observed 66. 
Further study demonstrated that there is a 2- to 3-fold variation in the binding of DMXAA (2) by plasma 
proteins in healthy humans and cancer patients. Unbound DMXAA (2) fraction in healthy humans was 
significantly less than that observed in cancer patients 68. Negligible gender differences occurred in 
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plasma protein binding of DMXAA (2) in mice, rats and humans 60. Albumin was the principal binding 
protein, with minor binding to human γ-globulin and α1-acid glycoprotein 66. Similar to preclinical 
studies, highly albumin-bound of DMXAA (2) and saturation of protein binding at higher doses were also 
described in clinical trials 63,71,187. For example, in a Phase I trial, at doses up to 320 mg.m-2, more than 
99% of DMXAA (2) was plasma protein bound; at higher doses (4900 mg.m-2) the percentage of free 
drug increased to a maximum of 6.9% 63. 
 
5.2. Metabolism and Elimination 
In vitro studies using isolated perfused rat liver, human liver microssomes as well as in vivo animal 
studies have revealed that conjugation of the acidic side chain with glucuronic acid and 6-
methylhydroxylation are the major metabolic pathways of DMXAA (2) 54,56,198,199. In all species studied, 
hepatic and renal DMXAA (2) acyl glucuronidation and 6-methylhydroxylation followed Michaelis-
Menten kinetics 56. Hepatic isozymes responsible for the metabolism of DMXAA (2) were identified, 
demonstrating that DMXAA (2) glucuronidation is catalyzed by uridine diphosphate 
glucuronosyltransferases (UGT1A9 and UGT2B7) 200, and 6-methylhydroxylation by cytochrome P450 
(CYP1A2) 201. The involvement of flavin-containing monooxygenase (FMO) in the 6-
methylhydroxylation of the DMXAA (2) was investigated by use of human liver microsomes and 
microsomes containing cDNA-expressed FMOs. The results confirmed that human FMO3 had the 
capacity to metabolize DMXAA (2), although with less significant role than CYP1A2 202. 
Additional studies were conducted in order to determine interindividual variations in the expression 
and activity of the major liver enzymes that metabolize DMXAA (2), indicating that there was a 6- and 5-
fold interindividual variation in the enzyme levels of CYP1A2 and UGT2B7, respectively 68. Using an 
established human liver bank, the relative contribution of each pathway to the metabolism of DMXAA 
(2) demonstrated to be subject not only to the protein levels of enzymes involved but also to the substrate 
concentration 203. For example, at 5 µM DMXAA (2), 6-methylhydroxylation and acyl glucuronidation 
contributed 26 and 76%, respectively, to its metabolism; at 350 µM of DMXAA (2) the relative 
contribution of each pathway to the metabolism were 7 and 93%, respectively. Furthermore, gender 
differences in the metabolism of DMXAA (2) in mice, rats and humans have been reported 60. In fact, 
using human liver microssomes, the DMXAA (2) was mainly metabolized by 6-methylhydroxylation in 
men; in contrast, a notably higher rate of DMXAA (2) glucuronidation occurred in women. 
Significant strain differences in DMXAA (2) acyl glucuronidation and 6-methylhydroxylation in 
mousse liver microssomes were also observed 67.  
The resultant metabolites, namely DMXAA acyl glucuronide (DMXAA-G) (36, Fig.15) and 6-
hydroxymethyl-5-methylxanthenone-4 acetic acid (6-OH-MXAA) (37, Fig.15), have been successfully 
identified and quantified in different biological matrixes including animal and human plasma, urine, 
faeces and microsomes during PK, particularly metabolism studies 54,56,60,63-65,67,68,72,198,200,202-204. 
Accordingly, DMXAA (2) and its major metabolites (DMXAA-G, 36 and 6-OH-MXAA, 37) are excreted 
in bile and urine 56,198,205. Using the isolated perfused rat liver model, DMXAA-G (36) was identified as 
the major biliary metabolite, and its presence in bile accounted for >50% of the DMXAA (2) dose. A total 
of 28% of DMXAA (2) was recovered unchanged in the perfusate, liver and bile 198. In urine of patients 
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receiving DMXAA (2), at least five metabolites of DMXAA (2) were observed, with up to 60% of the 
total dose excreted as DMXAA-G (36), 5.5% as 6-OH-MXAA (37) and 4.5% as the glucuronide of 6-
OH-MXAA (37) 205. This study also indicated that the major metabolite (DMXAA-G, 36) is chemically 
unstable under physiological conditions, undergoing enzymatic and non-enzymatic hydrolysis, molecular 
rearrangement and covalent binding to plasma proteins 205.  
 
Fig. 15. Chemical structures of the major metabolites of DMXAA (2): DMXAA-G (36) and 6-OH-
MXAA (37). 
 
In a recent Phase I study using radioactive technique, two novel metabolites were identified, a 
DMXAA dimer (38, Fig. 16) and a DMXAA dimer glucuronide conjugate (39, Fig. 16). Both metabolites 
were detected in plasma and feces, and the dimer glucuronide conjugate was also detected in urine 72. 
Once again, DMXAA-G (36) was the major metabolite excreted in urine and accounted for the 
elimination of between 32 and 48% of the administered dose. The 6-OH-MXAA (37) was the major 
metabolite excreted in the feces and accounted for the elimination of between 7 and 27% of the dose. The 
mean contributions of the urinary and fecal routes to the overall elimination of DMXAA (2) were 53.9% 
and 33.3% of the administered dose, respectively. Unchanged DMXAA (2) was the major radioactivity 
component detected in plasma within the first 24 h after dosing. However, it was eliminated mainly as 
metabolites. Actually, urinary and fecal excretion of unchanged DMXAA (2) accounted for only 10 and 
20% or less of the dose, respectively 72. Additionally, studies of DMXAA (2) metabolism by human 
intestinal Caco-2 cells revealed that DMXAA (2) was metabolized to a very small extent (up to 5%), 
suggesting that no considerable intestinal metabolism would take place when DMXAA (2) is orally 
administered 129. 
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Fig. 16. Chemical structures of two novel metabolites of DMXAA (2): DMXAA dimer (38) and 
DMXAA dimer glucuronide conjugate (39). 
 
Various anticancer drugs inhibited the major metabolic pathways of DMXAA (2) in human liver 
microsomes 55,61. Specifically, vinblastine, vincristine and amsacrine (500 µM) inhibited DMXAA (2) 
glucuronidation (inhibition constants (Ki) = 319, 350 and 230 µM, respectively), but not 6-
methylhydroxylation. On the other hand, daunorubicin and N-[2-(dimethylamino)-ethyl]acridine-4-
carboxamide (100 and 500 µM) showed inhibition of DMXAA (2) 6-methylhydroxylation (Ki  = 131 and 
0.59 µM, respectively), but not glucuronidation. It is important to emphasize that some drugs, such as 5-
fluoroucacil, paclitaxel, tirapazamine and methotrexate, exhibited insignificant inhibition of the 
metabolism of DMXAA (2) 61. These studies are fundamental in order to predict potential in vivo DDI as 
well as to establish doses of DMXAA (2) when used in combination with other common anticancer drugs. 
 
5.3. Pharmacokinetic parameters  
Prior to clinical evaluation of DMXAA (2), studies revealed differences among species in PK 
showing nonlinear plasma PK at MTD (maximum tolerated dose) 56,57. The PK of DMXAA (2) in cancer 
patients was also dose dependent, being the non-linearity remarkably consistent over a large dose range 
63,71,185. For example, peak plasma concentrations and area under the curve (AUC) level increased from 
4.8 µM and 3.2 µM h, respectively, at the lowest dose (6 mg.m-2) to 1290 µM and 7600 µM h at the MTD 
(3700 mg.m-2), while clearance declined from 7.4 to 1.7 l h-1.m-2 over the same dose range. The terminal 
elimination half-life for all patients was 8.1 ± 4.3 h 63.  
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The saturation of elimination mechanisms and plasma protein binding were the most plausible 
source for the non-linearity PK of DMXAA (2) 71,185,206. 
Based on the findings of dose-escalation Phase I trials, doses in the range of 1200 mg.m-2 of 
DMXAA (2) were selected for further combination studies 185. Specifically, at 1200 mg.m-2, the Cmax 
and the area under the concentration-time curve over 24 h for total and free DMXAA (2) plasma 
concentrations were 315 ± 25.8 µg.mL-1, 29 ± 6.4 µg.mL-1 day, 8.0 ± 1.77 µg.mL-1, and 0.43 ± 0.07 
µg.mL-1 day, respectively 185. Subsequently randomised phase II study in patients with NSCLC 
demonstrated that when DMXAA (2) (1200 mg.m-2) was co-administered with carboplatin and paclitaxel, 
there was little change in the systemic exposure or disposition of either total or free carboplatin or 
paclitaxel as well as total DMXAA (2). Nevertheless, the concentration of free DMXAA (2) was 
increased, suggesting that the chemotherapy drugs or excipients changed the partitioning of DMXAA (2) 
within plasma 188. Further clinical studies corroborated the feasibility of combining DMXAA (2) 
(elevated the dose to 1800 mg.m-2) with carboplatin and paclitaxel, emphasizing the absence of adverse 
PK interactions, in addition to safety profile and improvements in efficacy variables, and survival 187,189. 
However, some drugs such as thalidomide 70, diclofenac 207, cyproheptadine 208 have been shown to 
modulate the PK of DMXAA (2). 
DMXAA (2) exhibited good oral bioavailability (73%) in mice, but revealed low antitumor activity 
when given as a single dose 209. However, after multiple oral doses it gave a 90% cure rate of colon 38 
tumors 210. To better understand its oral PK properties, the intestinal absorption of DMXAA (2) and its 
major metabolite was characterized using human intestinal cell line Caco-2 monolayers 73,129.  
DMXAA (2) can be considered as a weak acid with a pKa of 5.5, being mainly present as ionized 
form at pH 7.4, whereas DMXAA-G (36) is a high hydrophilic conjugate with an approximate pKa of 3.5. 
The permeability coefficient (Papp) values of DMXAA (2) over 10-500µM were 4×10-5 cm/s to 4.3×10-5 
cm/s for both apical (AP) to basolateral (BL) and BL-AP transport, regardless of concentration. On the 
other hand, the Papp values for the BL to AP flux of DMXAA-G (36) were significantly greater than 
those for the AP to BL flux, with net efflux ratio (Rnet) values of 4.5-17.6 over 50-200. The transport of 
DMXAA-G (36) was energy and Na+- dependent and inhibited by MK-571, a multidrug resistance 
associated protein (MRP) 1/2 inhibitor. These results indicated that DMXAA (2) was passively 
transported by intestinal cells, whereas the transport of DMXAA-G (36) was mediated by multidrug 
resistance associated protein (MRP) 1/2 µM 73,129. The effect of other drugs on DMXAA (2) and 
DMXAA-G (36) transport, namely thalidomide, diclofenac, probenecid, verapamil, cimetidine were 
evaluated, but none showed any significant effect 129.  
 
Perspectives and conclusion 
 
For the physico-chemical and PK studies of xanthonic compounds, the chromatographic and 
spectrometric methods have been widely used as analytical tools for compounds detection, quantification, 
and metabolites identification. 
Currently, it is not only compounds biological activities that are important to become drug 
candidates, with physico-chemical and PK properties representing relevant roles to achieve drug-likeness. 
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Thus, at first it is desirable to study compounds physico-chemical properties, such as lipophilicity to 
predict a good balance between its aqueous solubility and permeability through the cells membranes. 
Preclinical studies should be directed in order to investigate the PK and toxicity early in the process of 
hit-to-lead optimization since they give valuable information in the analogue-based design. It is relevant 
to understand the bioavailability, exposure, distribution volume, plasma protein binding, metabolism and 
clearance. These key properties and their intrinsic parameters are interlinked and complement each other 
for a detailed characterization of the compound. 
The most investigated naturally-occurring xanthones are compounds with low aqueous solubility 
(range of 10-6 M) due to their planar scaffold and presence of prenyl and other hydrophobic groups. This 
affects absorption and volume distribution, and consequently compromises bioavailability. Nevertheless, 
chemical synthesis has allowed to introduce structural alterations in order to increase their solubility, such 
as: hydrophilic amine substitution, salt formation, introduction of hydroxyls and elimination of 
hydrophobic and/or bulky substituents. Such examples of these chemical alterations were highlighted for 
gambogic acid (6) and its synthetic derivatives and for pyranoxanthones. Studies with Caco-2 cell line 
indicated the high permeability of xanthones and predicted the observed good in vivo distribution. 
Mangiferin (3) and DMXAA (2) have been reported to extensively bind to plasma proteins.This potential 
limitation opens paths to explore DDI and dosing to guarantee further safety. Moreover, mangiferin (3), 
being poorly soluble in aqueous solutions and suffering dehydroxylation, metylation or deglucosydation 
as main metabolic reactions, shows a low rate of clearance.  
To perform all of these physico-chemical and PK assays it is important that compounds are stable 
during experiments and storage in biological and non-biological samples. In regards to stability, the 
studied xanthones are stable at different temperatures, time and solution pH values, excepting α-
mangostin (4) and mangiferin (3) in acidic solutions and the former also in oxidative environments. 
Overall, this physico-chemical and ADME/tox characterization has abled to dig underlying valuable 
information about xanthonic derivatives in order to guide the design and development of new chemical 
entities and further studies. The characterization of the metabolism is important to understand the 
metabolic pathways, possible DDI, the extent that xanthonic derivatives are metabolized (clearance) and 
further which metabolites could be active or are associated with toxicity. Once the structural soft spots for 
metabolism are identified they could be also valuable for further chemical synthesis design.   
In sum, having in mind the potential biological activities of xanthone derivatives and a deeper 
knowledge about their structure-properties relationships, it impels to the rational design of new 
derivatives aiming to reach their clinical application. 
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